Nsaids and increased blood pressure: What is the clinical significance?

Several randomised studies have demonstrated that various nonsteroidal anti-inflammatory drugs (NSAIDs) elevate blood pressure in normotensive and hypertensive individuals; however, these data have been contradicted by numerous negative studies. Two meta-analyses have demonstrated that, after poolin...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Drug safety 1997-11, Vol.17 (5), p.277-289
1. Verfasser: JOHNSON, A. G
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 289
container_issue 5
container_start_page 277
container_title Drug safety
container_volume 17
creator JOHNSON, A. G
description Several randomised studies have demonstrated that various nonsteroidal anti-inflammatory drugs (NSAIDs) elevate blood pressure in normotensive and hypertensive individuals; however, these data have been contradicted by numerous negative studies. Two meta-analyses have demonstrated that, after pooling data drawn from published reports of randomised trials of younger adults, NSAID use produces a clinically significant increment in mean blood pressure of 5 mm Hg, most marked in patients with controlled hypertension. Stratification by NSAID type revealed that piroxicam, naproxen and indomethacin had the greatest, and sulindac the smallest, pressor effect. These data were supported by 2 large community studies involving elderly patients. Recent NSAID users had a 1.7-fold higher risk of requiring the initiation of antihypertensive therapy compared with nonusers; NSAID users also had a 40% increased risk of receiving a diagnosis of hypertension compared with nonusers. It is vital to determine the nature of the association in the elderly, 12 to 15% of whom are concurrently receiving an NSAID and an antihypertensive agent. Importantly, a 5 to 6 mm Hg increase in diastolic blood pressure maintained over a few years may be associated with a 67% increase in total stroke risk and a 15% increase in coronary heart disease events. While the mechanism(s) remain speculative, salt and water retention through several factors operating in parallel, coupled with increased total peripheral vascular resistance, via increased renal endothelin-1 synthesis, are potentially important. Clinicians should strive to avoid excessive use of NSAID treatment and consider well-tolerated therapeutic alternatives, including simple analgesics and physical therapy. For patients who require concomitant NSAID and antihypertensive treatment, physicians should be aware that indomethacin, naproxen and piroxicam may be associated with a greater pressor effect than many other NSAIDs, and that antagonism of beta-blockers may be greater than that of vasodilators (including ACE inhibitors and calcium antagonists) and diuretics. Finally, the progress of each patient should be monitored by careful blood pressure measurement, particularly during the period of initiation of NSAID therapy.
doi_str_mv 10.2165/00002018-199717050-00001
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_17279070</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>17279070</sourcerecordid><originalsourceid>FETCH-LOGICAL-c315t-679a1327e91735e80ebf30ddd866052b04071a44fc8396259a305c678dd17c433</originalsourceid><addsrcrecordid>eNo9kMFOwzAMhnMAjTF4BKQcELdCnLRJwwWhCQbSBBcQxypNUhbUtSNuD7w9GRvzxdbv37b8EUKBXXOQxQ1LwRmUGWitQLGCZVsJjsiUAeRZoUGekFPEr6SWXJYTMtFCg1J8ShYvaIJDajpHQ2ejN-gdrdu-d3QTPeIY_S39WJmBBqTDylPbhi5Y01IMn11oUtlZf3dGjhvToj_f5xl5f3x4mz9ly9fF8_x-mVkBxZBJpQ0Irnw6LwpfMl83gjnnSilZwWuWMwUmzxtbCi15oY1ghZWqdA6UzYWYkavd3k3sv0ePQ7UOaH3bms73I1aguNJMsWQsd0Ybe8Tom2oTw9rEnwpYteVW_XOrDtz-JEijF_sbY7327jC4h5b6l_u-wQSiiYlAwIONp0ekFOIXmnx1QQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>17279070</pqid></control><display><type>article</type><title>Nsaids and increased blood pressure: What is the clinical significance?</title><source>MEDLINE</source><source>SpringerNature Journals</source><creator>JOHNSON, A. G</creator><creatorcontrib>JOHNSON, A. G</creatorcontrib><description>Several randomised studies have demonstrated that various nonsteroidal anti-inflammatory drugs (NSAIDs) elevate blood pressure in normotensive and hypertensive individuals; however, these data have been contradicted by numerous negative studies. Two meta-analyses have demonstrated that, after pooling data drawn from published reports of randomised trials of younger adults, NSAID use produces a clinically significant increment in mean blood pressure of 5 mm Hg, most marked in patients with controlled hypertension. Stratification by NSAID type revealed that piroxicam, naproxen and indomethacin had the greatest, and sulindac the smallest, pressor effect. These data were supported by 2 large community studies involving elderly patients. Recent NSAID users had a 1.7-fold higher risk of requiring the initiation of antihypertensive therapy compared with nonusers; NSAID users also had a 40% increased risk of receiving a diagnosis of hypertension compared with nonusers. It is vital to determine the nature of the association in the elderly, 12 to 15% of whom are concurrently receiving an NSAID and an antihypertensive agent. Importantly, a 5 to 6 mm Hg increase in diastolic blood pressure maintained over a few years may be associated with a 67% increase in total stroke risk and a 15% increase in coronary heart disease events. While the mechanism(s) remain speculative, salt and water retention through several factors operating in parallel, coupled with increased total peripheral vascular resistance, via increased renal endothelin-1 synthesis, are potentially important. Clinicians should strive to avoid excessive use of NSAID treatment and consider well-tolerated therapeutic alternatives, including simple analgesics and physical therapy. For patients who require concomitant NSAID and antihypertensive treatment, physicians should be aware that indomethacin, naproxen and piroxicam may be associated with a greater pressor effect than many other NSAIDs, and that antagonism of beta-blockers may be greater than that of vasodilators (including ACE inhibitors and calcium antagonists) and diuretics. Finally, the progress of each patient should be monitored by careful blood pressure measurement, particularly during the period of initiation of NSAID therapy.</description><identifier>ISSN: 0114-5916</identifier><identifier>DOI: 10.2165/00002018-199717050-00001</identifier><identifier>PMID: 9391772</identifier><language>eng</language><publisher>Auckland: Adis international</publisher><subject>Adult ; Anti-Inflammatory Agents, Non-Steroidal - adverse effects ; Biological and medical sciences ; Blood Pressure - drug effects ; Drug toxicity and drugs side effects treatment ; Humans ; Hypertension - chemically induced ; Hypertension - epidemiology ; Hypertension - pathology ; Medical sciences ; Pharmacology. Drug treatments ; Randomized Controlled Trials as Topic ; Toxicity: cardiovascular system</subject><ispartof>Drug safety, 1997-11, Vol.17 (5), p.277-289</ispartof><rights>1998 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,782,786,27931,27932</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=2052663$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/9391772$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>JOHNSON, A. G</creatorcontrib><title>Nsaids and increased blood pressure: What is the clinical significance?</title><title>Drug safety</title><addtitle>Drug Saf</addtitle><description>Several randomised studies have demonstrated that various nonsteroidal anti-inflammatory drugs (NSAIDs) elevate blood pressure in normotensive and hypertensive individuals; however, these data have been contradicted by numerous negative studies. Two meta-analyses have demonstrated that, after pooling data drawn from published reports of randomised trials of younger adults, NSAID use produces a clinically significant increment in mean blood pressure of 5 mm Hg, most marked in patients with controlled hypertension. Stratification by NSAID type revealed that piroxicam, naproxen and indomethacin had the greatest, and sulindac the smallest, pressor effect. These data were supported by 2 large community studies involving elderly patients. Recent NSAID users had a 1.7-fold higher risk of requiring the initiation of antihypertensive therapy compared with nonusers; NSAID users also had a 40% increased risk of receiving a diagnosis of hypertension compared with nonusers. It is vital to determine the nature of the association in the elderly, 12 to 15% of whom are concurrently receiving an NSAID and an antihypertensive agent. Importantly, a 5 to 6 mm Hg increase in diastolic blood pressure maintained over a few years may be associated with a 67% increase in total stroke risk and a 15% increase in coronary heart disease events. While the mechanism(s) remain speculative, salt and water retention through several factors operating in parallel, coupled with increased total peripheral vascular resistance, via increased renal endothelin-1 synthesis, are potentially important. Clinicians should strive to avoid excessive use of NSAID treatment and consider well-tolerated therapeutic alternatives, including simple analgesics and physical therapy. For patients who require concomitant NSAID and antihypertensive treatment, physicians should be aware that indomethacin, naproxen and piroxicam may be associated with a greater pressor effect than many other NSAIDs, and that antagonism of beta-blockers may be greater than that of vasodilators (including ACE inhibitors and calcium antagonists) and diuretics. Finally, the progress of each patient should be monitored by careful blood pressure measurement, particularly during the period of initiation of NSAID therapy.</description><subject>Adult</subject><subject>Anti-Inflammatory Agents, Non-Steroidal - adverse effects</subject><subject>Biological and medical sciences</subject><subject>Blood Pressure - drug effects</subject><subject>Drug toxicity and drugs side effects treatment</subject><subject>Humans</subject><subject>Hypertension - chemically induced</subject><subject>Hypertension - epidemiology</subject><subject>Hypertension - pathology</subject><subject>Medical sciences</subject><subject>Pharmacology. Drug treatments</subject><subject>Randomized Controlled Trials as Topic</subject><subject>Toxicity: cardiovascular system</subject><issn>0114-5916</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1997</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo9kMFOwzAMhnMAjTF4BKQcELdCnLRJwwWhCQbSBBcQxypNUhbUtSNuD7w9GRvzxdbv37b8EUKBXXOQxQ1LwRmUGWitQLGCZVsJjsiUAeRZoUGekFPEr6SWXJYTMtFCg1J8ShYvaIJDajpHQ2ejN-gdrdu-d3QTPeIY_S39WJmBBqTDylPbhi5Y01IMn11oUtlZf3dGjhvToj_f5xl5f3x4mz9ly9fF8_x-mVkBxZBJpQ0Irnw6LwpfMl83gjnnSilZwWuWMwUmzxtbCi15oY1ghZWqdA6UzYWYkavd3k3sv0ePQ7UOaH3bms73I1aguNJMsWQsd0Ybe8Tom2oTw9rEnwpYteVW_XOrDtz-JEijF_sbY7327jC4h5b6l_u-wQSiiYlAwIONp0ekFOIXmnx1QQ</recordid><startdate>19971101</startdate><enddate>19971101</enddate><creator>JOHNSON, A. G</creator><general>Adis international</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T2</scope><scope>7U2</scope><scope>7U7</scope><scope>C1K</scope></search><sort><creationdate>19971101</creationdate><title>Nsaids and increased blood pressure: What is the clinical significance?</title><author>JOHNSON, A. G</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c315t-679a1327e91735e80ebf30ddd866052b04071a44fc8396259a305c678dd17c433</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1997</creationdate><topic>Adult</topic><topic>Anti-Inflammatory Agents, Non-Steroidal - adverse effects</topic><topic>Biological and medical sciences</topic><topic>Blood Pressure - drug effects</topic><topic>Drug toxicity and drugs side effects treatment</topic><topic>Humans</topic><topic>Hypertension - chemically induced</topic><topic>Hypertension - epidemiology</topic><topic>Hypertension - pathology</topic><topic>Medical sciences</topic><topic>Pharmacology. Drug treatments</topic><topic>Randomized Controlled Trials as Topic</topic><topic>Toxicity: cardiovascular system</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>JOHNSON, A. G</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Health and Safety Science Abstracts (Full archive)</collection><collection>Safety Science and Risk</collection><collection>Toxicology Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><jtitle>Drug safety</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>JOHNSON, A. G</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Nsaids and increased blood pressure: What is the clinical significance?</atitle><jtitle>Drug safety</jtitle><addtitle>Drug Saf</addtitle><date>1997-11-01</date><risdate>1997</risdate><volume>17</volume><issue>5</issue><spage>277</spage><epage>289</epage><pages>277-289</pages><issn>0114-5916</issn><abstract>Several randomised studies have demonstrated that various nonsteroidal anti-inflammatory drugs (NSAIDs) elevate blood pressure in normotensive and hypertensive individuals; however, these data have been contradicted by numerous negative studies. Two meta-analyses have demonstrated that, after pooling data drawn from published reports of randomised trials of younger adults, NSAID use produces a clinically significant increment in mean blood pressure of 5 mm Hg, most marked in patients with controlled hypertension. Stratification by NSAID type revealed that piroxicam, naproxen and indomethacin had the greatest, and sulindac the smallest, pressor effect. These data were supported by 2 large community studies involving elderly patients. Recent NSAID users had a 1.7-fold higher risk of requiring the initiation of antihypertensive therapy compared with nonusers; NSAID users also had a 40% increased risk of receiving a diagnosis of hypertension compared with nonusers. It is vital to determine the nature of the association in the elderly, 12 to 15% of whom are concurrently receiving an NSAID and an antihypertensive agent. Importantly, a 5 to 6 mm Hg increase in diastolic blood pressure maintained over a few years may be associated with a 67% increase in total stroke risk and a 15% increase in coronary heart disease events. While the mechanism(s) remain speculative, salt and water retention through several factors operating in parallel, coupled with increased total peripheral vascular resistance, via increased renal endothelin-1 synthesis, are potentially important. Clinicians should strive to avoid excessive use of NSAID treatment and consider well-tolerated therapeutic alternatives, including simple analgesics and physical therapy. For patients who require concomitant NSAID and antihypertensive treatment, physicians should be aware that indomethacin, naproxen and piroxicam may be associated with a greater pressor effect than many other NSAIDs, and that antagonism of beta-blockers may be greater than that of vasodilators (including ACE inhibitors and calcium antagonists) and diuretics. Finally, the progress of each patient should be monitored by careful blood pressure measurement, particularly during the period of initiation of NSAID therapy.</abstract><cop>Auckland</cop><pub>Adis international</pub><pmid>9391772</pmid><doi>10.2165/00002018-199717050-00001</doi><tpages>13</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0114-5916
ispartof Drug safety, 1997-11, Vol.17 (5), p.277-289
issn 0114-5916
language eng
recordid cdi_proquest_miscellaneous_17279070
source MEDLINE; SpringerNature Journals
subjects Adult
Anti-Inflammatory Agents, Non-Steroidal - adverse effects
Biological and medical sciences
Blood Pressure - drug effects
Drug toxicity and drugs side effects treatment
Humans
Hypertension - chemically induced
Hypertension - epidemiology
Hypertension - pathology
Medical sciences
Pharmacology. Drug treatments
Randomized Controlled Trials as Topic
Toxicity: cardiovascular system
title Nsaids and increased blood pressure: What is the clinical significance?
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-04T04%3A02%3A41IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Nsaids%20and%20increased%20blood%20pressure:%20What%20is%20the%20clinical%20significance?&rft.jtitle=Drug%20safety&rft.au=JOHNSON,%20A.%20G&rft.date=1997-11-01&rft.volume=17&rft.issue=5&rft.spage=277&rft.epage=289&rft.pages=277-289&rft.issn=0114-5916&rft_id=info:doi/10.2165/00002018-199717050-00001&rft_dat=%3Cproquest_cross%3E17279070%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=17279070&rft_id=info:pmid/9391772&rfr_iscdi=true